Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen Macarena (10)

2022

  1. Human Omental Mesothelial Cells Impart an Immunomodulatory Landscape Impeding B-and T-Cell Activation

    International Journal of Molecular Sciences, Vol. 23, Núm. 11

2020

  1. Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus (Frontiers in Immunology, (2019), 10, 10.3389/fimmu.2019.01151)

    Frontiers in Immunology

2019

  1. Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus

    Frontiers in Immunology, Vol. 10, Núm. JUN

2018

  1. Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study

    PLoS ONE, Vol. 13, Núm. 5

  2. PDGF Restores the Defective Phenotype of Adipose-Derived Mesenchymal Stromal Cells from Diabetic Patients

    Molecular Therapy, Vol. 26, Núm. 11, pp. 2696-2709

2015

  1. Myocardial ischemic subject's thymus fat: A novel source of multipotent stromal cells

    PLoS ONE, Vol. 10, Núm. 12

2010

  1. Blocking of melatonin synthesis and MT1 receptor impairs the activation of Jurkat T cells

    Cellular and Molecular Life Sciences, Vol. 67, Núm. 18, pp. 3163-3172

2002

  1. Fragile X founder effect and distribution of CGG repeats among the mentally retarded population of Andalusia, South Spain

    Genetics and Molecular Biology, Vol. 25, Núm. 1, pp. 1-6

1999

  1. Phenylarsine oxide increases intracellular calcium mobility and inhibits Ca2+-dependent ATPase activity in thymocytes

    Molecular Genetics and Metabolism, Vol. 68, Núm. 3, pp. 363-370

1998

  1. Assessment of FMR1 expression by reverse transcriptase-polymerase chain reaction of KH domains

    Journal of Laboratory and Clinical Medicine, Vol. 131, Núm. 2, pp. 170-173